Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
-
Access it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of its latest CEO Corner segment,...
-
Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Tumor Microenvironment (TME) Modulation Market - Strategic Insights and Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. ...
-
Urteste S.A. Receives U.S. Patent for the Panuri Test Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange:...
-
OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer...
-
OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series...
-
OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final subject has received their first dose in the Phase 2...
-
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat...
-
Immuneering Appoints Andrew Gengos as Chief Financial Officer
-
Urteste S.A. enrolled the first patient in the Panuri pancreatic cancer study; interim analysis results are expected in Q4 2026.